BioLineRx Ltd. (NASDAQ:BLRX) Upgraded by Zacks Investment Research to Hold
Zacks Investment Research upgraded shares of BioLineRx Ltd. (NASDAQ:BLRX) from a sell rating to a hold rating in a research note published on Wednesday.
According to Zacks, “Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company’s portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. “
Other analysts have also recently issued research reports about the company. HC Wainwright set a $4.00 target price on BioLineRx and gave the stock a buy rating in a report on Saturday, June 3rd. Maxim Group upgraded BioLineRx from a hold rating to a buy rating and increased their target price for the stock from $1.00 to $3.00 in a report on Thursday, May 18th. Finally, ValuEngine upgraded BioLineRx from a sell rating to a hold rating in a report on Monday, July 17th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $3.18.
Shares of BioLineRx (BLRX) opened at 0.993 on Wednesday. The firm has a 50-day moving average of $0.88 and a 200 day moving average of $0.96. The stock’s market capitalization is $61.35 million. BioLineRx has a one year low of $0.75 and a one year high of $1.42.
BioLineRx (NASDAQ:BLRX) last announced its earnings results on Thursday, May 25th. The biotechnology company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.03. On average, equities research analysts predict that BioLineRx will post ($0.24) EPS for the current year.
COPYRIGHT VIOLATION WARNING: This story was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/biolinerx-ltd-nasdaqblrx-upgraded-by-zacks-investment-research-to-hold/1462312.html.
Several institutional investors have recently modified their holdings of BLRX. Sabby Management LLC purchased a new position in shares of BioLineRx during the first quarter valued at about $3,018,000. KCG Holdings Inc. raised its position in shares of BioLineRx by 715.9% in the first quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 153,687 shares during the period. Renaissance Technologies LLC purchased a new position in shares of BioLineRx during the first quarter valued at about $126,000. Citadel Advisors LLC raised its position in shares of BioLineRx by 443.4% in the first quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 86,481 shares during the period. Finally, Benchmark Capital Advisors raised its position in shares of BioLineRx by 227.3% in the first quarter. Benchmark Capital Advisors now owns 144,000 shares of the biotechnology company’s stock valued at $138,000 after buying an additional 100,000 shares during the period. 38.00% of the stock is currently owned by institutional investors and hedge funds.
BioLineRx Company Profile
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.